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Abstract Giant cell tumor (GCT) of the bone, also called
osteoclastoma, is a rare complication of Paget’sb o n e
disease. We report a patient from Southern Italy who
developed a GCT infiltrating the neighboring tissues. The
natural history and the therapeutic outcomes of this unique
complication of Paget’s bone disease are presented.
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Introduction
Paget’sd i s e a s eo fb o n e( P D B )i sac o m m o ns l o w l y
progressive disorder due to abnormal ostoclastic–osteoblastic
remodeling resulting in deformity and enlargement of single
or multiple bones. The cause of PDB is incompletely
understood, but genetic factors have clearly an important
role as roughly, 15% of patients have a positive family
history. Moreover, mutations causing this disease or related
syndromes have been identified in four genes [1]. The most
important gene for PDB is Sequestosome 1 (SQSTM1/p62)
encoding a protein implicated in pre-osteoclast recruitment
and maturation and a molecular partner of the NFκB-
signaling pathway [2]. Several other loci have been identified
by genome-wide linkage association studies [3].
Major complications of PDB include bone deformities
and fractures, osteoarthritis, and more rarely, high-output
cardiac failure. The development of malignancy, usually
osteosarcomas, is reported to occur in <1% of cases [4–6].
The majority of these tumors are classified as osteogenic
osteosarcomas [7], but benign giant cell tumors (GCTs),
otherwise known as osteoclastomas, may also occur [8].
GCTs occur more frequently in patients with the polyostotic
form of PDB and usually involve the skull and facial bones
and, less frequently, the pelvis and the spine. These tumors
are histological and clinically benign and they usually
remain confined to the affected bone.
Case report
We report the case of a male patient from the region of
Campania, a region of Southern Italy including the town of
Avellino, who was first diagnosed with a polyostotic PDB
at the age of 35 years. His medical history was significant
for obesity, diverticulosis, benign prostatic hypertrophy, and
mild hearing loss. The PDB was under control without any
medical treatment until the age of 68 years when the patient
developed back pain which was initially mild and localized,
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DOI 10.1007/s11657-009-0027-7but it progressively worsened and extended to the lumbar
and left iliac region. The pain was more severe with
physical activity and was only partially relieved by
NSAIDs. A slow-growing palpable mass in the left anterior
abdominal region and a single episode of hematuria were
also reported. He had no history of fracture. His family
history was significant for his daughter who was also
affected by PDB diagnosed when she was 20 years old and
treated with biphosphonate. The physical examination
confirmed the presence of a firm mass extending from the
left iliac bone to the anterior abdominal region. The
ultrasound and the abdominal–pelvic CT scan both indica-
ted the presence of a lesion with irregular margins, with a
diameter of approximately 8 cm and tightly adherent to the
ileum and left ischio-pubic bones (Fig. 1). The lesion was
found to infiltrate the rectum, the distal portion of the left
ureter and the bladder. The X-rays of the pelvis (Fig. 2) and
lower limbs showed cortical thickening and sclerosis of the
multiloculated lytic lesions of the iliac bones. The cortex of
the long bones of both upper and lower extremities was
coarse and thickened. The bone scintigraphy showed
increased uptake in multiple sites including the skull,
vertebral bodies, proximal regions of the humeri, pelvic
bones, and proximal femurs bilaterally (Fig. 3). His total
serum alkaline phosphatase activity (1,346 IU/L; normal
range, 8–300 IU/L) and bone-specific fraction (230.3 IU/L;
normal range: 6-16 IU/L) were both significantly elevated.
PTH (18.3 pg/ml; normal range 10–65 pg/ml), urinary
deoxypyridoline (3.8 UI; normal range, 2.5–5.5 UI), osteo-
calcin (13.4 ng/ml; normal range, 5–18 ng/ml), 25-0HD
(22.6 ng/ml; normal range, 9.2–45.2 ng/ml), ESR, and C-
reactive protein were all within the normal ranges.
Fig. 1 3D-CT scan of the tumor lesion showing irregular margins,
with a diameter of approximately 8 cm and tightly adherent to the
ileum and left ischio-pubic bones
Fig. 2 Pelvis X-ray showing the typical mixed appearance of areas of
osteolysis and sclerosis
Fig. 3 Anterior (left) and posterior (right) technetium-99m-labeled
diphosphonate bone scintigraphy showing multiple sites of increased
uptake
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showed the presence of giant multinucleated cells consistent
with GCT (Fig. 4a). This cell population showed a
granulomatosis-like pattern of appearance and was associa-
ted with lympho-monocyte and eosinophilic components.
Biopsy sample obtained from the bladder through a
cystoscopy performed for investigation of the hematuria,
showed complete integrity of urothelial epithelium, while the
chorion and muscolar tunica showed an infiltrate constituted
by monuclear cells and giant multinucleated cells within an
edematous-myxoid stroma. These features were compatible
with ab extrinseco infiltration by the GCT (Fig. 4b).
The patient was started on dexamethasone therapy by
intramuscular injections at a dosage of 8–12 mg/day for
3 weeks in combination with intramuscular clodronate
100 mg, every 3 days for the first 3 weeks, then weekly.
In the subsequent 5 months, dexamethasone was gradually
reduced to a daily maintenance dose of 0.75 mg/day given
orally. The treatment resulted in a good clinical response
with normalization of serum ALP and pain resolution about
1 week after the treatment was started. The patient
remained pain-free at the following evaluations performed
1 and 6 months after the beginning of treatment. A control
pelvic CT scan performed after 1 and 6 months of therapy
indicated a reduction in size of the pelvic mass but
persistence of the parietal bladder infiltration. The CT
control at 6 months showed a substantial stabilization of the
disease, while there was a gradual reduction, until normal-
ization, of serum ALP.
Because of the occurrence of corticosteroid effects and
because of the finding of high vascularization of the tumor
on angiography, a selective arterial embolization was
attempted as an alternative to steroid treatment. Three
months after the embolization, the lesion remained stable.
However, after suspension of corticosteroid therapy, the
patient started experiencing pain in sacral region again
which was associated with left leg claudication, and with a
new rise in serum ALP levels. Therefore, an alternative
treatment was started with intravenous infusion of 4 mg of
zoledronic acid every 3 weeks for four cycles and this
resulted in good control of bone pain, normalization of the
serum ALP but no effect on the tumor size.
Previous reports showed a relatively frequent involve-
ment of mutations of SQSTM1/p62 gene in both sporadic
and familial Italian PDB cases [7–9]. Consequently, after
obtaining a signed informed consent, genomic DNA
extracted from peripheral blood lymphocytes (NucleoSpin
Blood Quick Pure, Macherey-Nagel, Easton, PA, USA) and
tested for mutations in the SQSTM1/p62 gene coding
sequence by automated DNA sequencing (Applied Bio-
systems, Foster City, CA, USA). However, no mutations
were detected.
Discussion
The occurrence of neoplasms, including osteosarcoma,
fibrosarcoma, and chondrosarcoma, as a complication of
PDB is an infrequent event (<1%) [5]. GCT is an even rarer
complication of PDB and the mechanisms involved in the
pathogenesis of this tumor are unclear. GCT is usually a
benign and remains limited to the bone. Malignant
degeneration appears to be a rare event [9].
Treatment of this complication is problematic. A
dramatic response to corticosteroid treatment has been
reported in a few cases of GCT [10–12]. However, a fairly
rapid resumption of disease has also been reported upon
steroids discontinuation. In our case, continuous corticoste-
roid administration contributed to the stabilization of the
disease at the clinical, biochemical, and radiological levels.
Unfortunately, the lack of mass reduction and the occur-
rence of corticosteroid side effects required the discontin-
Fig. 4 a H&E of pelvic biopsy specimen. Detail of giant cell
osteoclast-like in GCT (arrow) in an edematous background contain-
ing mainly mononuclear cells. b H&E Neoplastic mononuclear and
giant cells infiltrating muscular cells (arrow) of bladder wall
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in significant cytoreduction but intravenous zoledronate led
to a good clinical response in terms of pain control and
serum ALP reduction.
The visceral and soft tissue infiltration from a GCT has
not been reported so far and it highlights the potential
malignant behavior of this type of lesions. Interestingly,
although mutation of SQSTM1/p62 gene has not been
detected, either the familial history (a daughter also affected
by PDB) or the early age of occurrence of PDB in both
subjects strongly suggested an inherited genetic cause.
Thus, our case suggests that different loci could be involved
in the pathogenesis of PDB and PDB-related GCT.
However, the pathogenesis of PDB and of the GCT remains
enigmatic and the role of yet unknown environmental factor
(s) such as measles or other viruses [10, 13, 14] cannot be
excluded. Our patient originates from Campania, a region
in which a concentration of PDB cases has been previously
reported [10, 15, 16], but not from the rural area of Avellino
from where previous cases developing GCT have been
reported [8, 16, 17].
In summary, we present a case of polyostotic PDB
complicated by the development of a GCT infiltrating the
neighboring tissue in the pelvis including the bladder. The
development of GCT in PDB is rare and treatment
particularly challenging. A more detailed molecular char-
acterization of known genes and the discovery of new
genetic and environmental mechanisms may improve our
understanding of GCT and enhance our ability to diagnose
and appropriately treat these patients.
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